$ACB

Small caps to watch: Curaleaf makes hostile bid for Aurora. Plus, Cargojet, Cineplex, AGT Food, Altius Minerals and several REITs expected to see active trading today

Curaleaf Holdings (CURA-T) announced a hostile bid for Aurora Cannabis (ACB-T) valuing the offer at US$4 per Aurora share, including 0.3463 Curaleaf shares and US$0.75 cash, a 45% premium to 30-day VWAP. Other updates: Pet Valu (PET-T) Q2 revenue $290.7M and beat; Organigram (OGI-T) Q3 revenue $105.8M beat; Cineplex (CGX-T) mixed; H&R REIT (HR-UN-T) to sell GO Residential REIT (GO-U-T) for about $6.7B; Cargojet (CJT-T) Q2 revenue $275.8M beat, adjusted EPS miss.

Original reporting
Published Aug 11, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 1:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Small caps to watch: Curaleaf makes hostile bid for Aurora. Plus, Cargojet, Cineplex, AGT Food, Altius Minerals and several REITs expected to see active trading today — source image
Decision brief

The 30-second read

$ACBBullishMed
01

Why it matters

Traders can act on (1) immediate takeover odds and premium repricing for CURA and ACB, (2) earnings-driven sentiment shifts for PET, OGI, CGX, and (3) event-driven deal positioning for HR-UN, plus (4) earnings reaction trade setup for CJT given the revenue beat but adjusted EPS miss.

02

Market read

This is a multi-catalyst day for Canadian small caps, dominated by a hostile cannabis M&A headline and several quantified earnings releases.

03

What to watch

For earnings names, adjusted metrics quality matters (e.g., Organigram’s net income boosted by non-cash fair value gains), and for Cargojet the key is whether the adjusted miss reflects sustainable margin pressure or timing.

Relevance 8/10Novelty 7/10Timing: pre-market today for several earnings prints; takeover headline is immediate

Background

The article is a small-cap watchlist updated through the day, covering one hostile takeover attempt and several pre-market earnings updates plus a major REIT asset sale.

Company-level read

Ticker impact

$ACBBullishMedium confidence
Context

Aurora is the target of Curaleaf’s hostile offer at US$4 per share, including 0.3463 Curaleaf shares and US$0.75 cash.

Expected impact

Likely upside bias with elevated volatility until Aurora responds or a formal bid process begins.

Evidence & confidence

The text discloses concrete offer terms and premium levels, but explicitly states there is no assurance the offer will be made.

$OGIBullishMedium confidence
Context

Organigram reported Q3 revenue of $105.8 million and adjusted EBITDA of $13.4 million, both ahead of expectations.

Expected impact

Potentially positive near-term price action as traders re-rate earnings power versus prior-year losses.

Evidence & confidence

The article provides specific beat figures and explains net income increase via non-cash fair value gains, which can temper quality concerns.

Market effects

Cannabis and small-cap Canadian equities may see cross-name sympathy trading on takeover premium and earnings beats/misses.

Could increase volatility in the TSX small-cap complex as multiple names report or face corporate actions on the same day.

Limited beyond North American small-cap sentiment, except for any broader cannabis M&A read-through.

Counterpoint

Hostile bids often fail or get re-priced; Aurora may resist, and the offer’s uncertainty can cap upside despite the headline premium.

Key entities

  • Curaleaf Holdings Inc.

    Announced a hostile bid for Aurora with specific per-share consideration and premium levels.

  • Aurora Cannabis Inc.

    Target of the hostile offer; deal terms and premium are disclosed in the article.

  • H&R REIT

    Agreed to sell all assets to GO Residential REIT for about $6.7 billion, expected to close in Q4.

  • GO Residential REIT

    Buyer in the H&R REIT asset sale transaction, with a pro forma ownership stake described.

Related articles

$ACBMed

Aurora Rejects Curaleaf's Hostile Bid and Opens the Door to Other Suitors

Aurora Cannabis rejected Curaleaf's hostile bid, valuing it at $4 per share. Aurora's board seeks other strategic options, citing undervaluation and growth prospects. Curaleaf's offer included cash and stock, with a cap of $5 per share. Aurora highlights its debt-free status and cash reserves, while Curaleaf points to Aurora's recent share sales and dilution.

$ACBMed

Aurora CEO Miguel Martin Says Curaleaf's $5 Bid Undervalues EU-Certified Cannabis Assets — BigGo Finance

Aurora Cannabis CEO Miguel Martin rejected Curaleaf's $5 per share takeover bid, citing undervaluation of Aurora's EU-certified cannabis assets. Martin highlighted Aurora's debt-free status, cash reserves, and the strategic value of its EU GMP-certified facilities, which are crucial for accessing key medical cannabis markets. The board, supported by an independent committee, believes the offer undervalues the company and invites better offers.

$ACBHighAI 8/10

Aurora Cannabis Fires Back at Curaleaf’s Hostile Takeover Bid - Aurora Cannabis (NASDAQ:ACB)

Aurora Cannabis (ACB) urged shareholders to reject Curaleaf's (CURLF) hostile takeover bid, calling it undervalued and risky. The board cited Curaleaf's $1B debt, lack of control premium, and potential dilution of shareholder rights. Aurora highlighted its debt-free status, cash reserves, and strong growth prospects. ACB shares were down 0.74% at $4.01 on Wednesday.

$CURLFMed

Curaleaf Responds After Aurora Board Unanimously Recommends Shareholders Reject Takeover Bid

Curaleaf Holdings defended its takeover bid for Aurora Cannabis, arguing its offer provides a 45% premium and long-term benefits. Aurora's board unanimously recommended shareholders reject the bid, citing undervaluation and risks. Curaleaf criticized Aurora's financial outlook and equity dilution, while Aurora maintained the offer undervalues the company. Curaleaf reported positive cash flow and growth investments for 2026.